Sheelu Varghese
Overview
Explore the profile of Sheelu Varghese including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
457
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Andrys-Olek J, Chellakkan Selvanesan B, Varghese S, Arriaza R, Tiwari P, Chruszcz M, et al.
Int J Mol Sci
. 2023 Aug;
24(16).
PMID: 37628960
TGF-β signaling promotes migration, invasion, and distant colonization of cancer cells in advanced metastatic cancers. TGF-β signaling suppresses the anti-tumor immune response in a tumor microenvironment, allowing sustained tumor growth....
2.
Chellakkan Selvanesan B, Pulido A, Varghese S, Rohila D, Hupalo D, Gusev Y, et al.
Cancers (Basel)
. 2023 Mar;
15(5).
PMID: 36900259
NSC243928 induces cell death in triple-negative breast cancer cells in a LY6K-dependent manner. NSC243928 has been reported as an anti-cancer agent in the NCI small molecule library. The molecular mechanism...
3.
Chellakkan Selvanesan B, Varghese S, Andrys-Olek J, Arriaza R, Prakash R, Tiwari P, et al.
Cancer Lett
. 2023 Feb;
558:216094.
PMID: 36805500
Lymphocyte antigen 6K (LY6K) is a small GPI-linked protein that is normally expressed in testes. Increased expression of LY6K is significantly associated with poor survival outcomes in many solid cancers,...
4.
Prakash R, Goodlett D, Varghese S, Andrys J, Gbadamosi F, Arriaza R, et al.
Bioorg Med Chem
. 2023 Jan;
79:117171.
PMID: 36680947
Small molecule NSC243928 binds with LY6K, a potential target for the treatment of triple-negative breast cancer, and induces cancer cell death with an unclear mechanism. We have developed chemical tools...
5.
Varghese S, Whipple R, Martin S, Alexander H
PLoS One
. 2013 Jan;
7(12):e52825.
PMID: 23285196
During the progression of malignant peritoneal mesothelioma (MPeM), tumor nodules propagate diffusely within the abdomen and tumors are characterized by distinct phenotypic sub-types. Recent studies in solid organ cancers have...
6.
Turner K, Varghese S, Alexander Jr H
J Natl Compr Canc Netw
. 2012 Jan;
10(1):49-57.
PMID: 22223869
Diffuse malignant peritoneal mesothelioma (DMPM) is a rare and ultimately fatal cancer that was first recognized and described a century ago. It is a diffuse primary malignant condition arising from...
7.
Turner K, Varghese S, Alexander Jr H
Curr Treat Options Oncol
. 2011 Mar;
12(2):189-200.
PMID: 21445576
Malignant peritoneal mesothelioma (MPM) is a rare, progressive, and ultimately fatal disease in almost all afflicted individuals. MPM is a cancer that arises diffusely from the serosa of the abdominal...
8.
Varghese S, Chen Z, Bartlett D, Pingpank J, Libutti S, Steinberg S, et al.
Cancer
. 2010 Sep;
117(2):361-71.
PMID: 20839315
Background: Malignant peritoneal mesothelioma (MPM) is a rare malignancy of the serosal membranes of the abdominal cavity. This cancer is ultimately fatal in almost all afflicted individuals; however, there is...
9.
Varghese S, Xu H, Bartlett D, Hughes M, Pingpank J, Beresnev T, et al.
Ann Surg Oncol
. 2010 Mar;
17(7):1870-7.
PMID: 20221901
Background: Patients with ocular melanoma liver metastases have a poor prognosis, treatment options are limited, and median survival is less than 1 year. In this study, we characterized the early...
10.
Varghese S, Burness M, Xu H, Beresnev T, Pingpank J, Alexander H
Ann Surg Oncol
. 2007 Sep;
14(12):3460-71.
PMID: 17899288
Background: Generally, colorectal and high-grade appendiceal cancers are treated similarly; treatment approach is primarily based on tumor histology and stage of disease. Patients with adenocarcinoma of the lower gastrointestinal tract...